EDX Medical expands its cancer testing capability

EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced a strategic expansion of its cancer testing capability.

EDX Medical is to launch comprehensive hereditary germline cancer testing products and services designed to accurately predict if family members of cancer patients are at increased risk from the disease.

The first test to be made available to health professionals in the UK is a pan-cancer test which achieves 99% sensitivity and identifies mutations in 70 genes known to be associated with cancers which have a strong inherited, genetic component including prostate, breast, colorectal, pancreatic and ovarian cancers in a single test.

EDX Medical’s comprehensive hereditary germline cancer testing products will enable doctors to advise family members of cancer patients on lifestyle choices and actions they can take to delay or prevent onset of the disease. Family members include grandparents, parents, children, siblings and other blood relatives.

The test will be available later this summer through private healthcare providers and via specific NHS Genetic and Genomic Testing Centres in cases where family members of cancer patients can be screened for genetic risk of cancer. In addition, EDX Medical will provide a support service for healthcare professionals with the test

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
EDX Medical Group plc

More articles like this

EDX Medical Group plc

EDX Medical Chairman and Founder provide shareholder update

EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services for the personalised treatment for cancer, heart disease and infectious diseases, has announced that Jason Holt, Chairman of the Company, and Prof. Sir Chris Evans, Founder

EDX Medical Group plc

EDX Medical signs distribution agreement with Caris Life Sciences

EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced it has signed a distribution agreement with Caris Life Sciences® (Caris), a leading US-based next-generation

EDX Medical Group plc

EDX Medical gains strong backing to revolutionise healthcare

Andrew Lloyd Webber, renowned for his iconic musicals, has invested in EDX Medical, a pioneering company focused on transforming the diagnosis and treatment of cancer, heart disease, and hospital infections. Founded by scientist Sir Chris Evans

EDX Medical Group plc

Understanding cancer’s genetic origins

Cancer is fundamentally a genetic disease caused by alterations in the genes that regulate cell growth and reproduction. These alterations, or mutations, can occur due to several factors, such as random errors during cell division, exposure

EDX Medical Group plc

Understanding how genetics influence cancer risk

Your genome, an extensive set of genetic material composed of approximately 3 billion pieces of DNA, serves as the master instruction manual for your body. Every cell within your body contains this entire genome. If you

EDX Medical Group plc

Understanding genetic testing and its role in cancer risk

Genetic testing involves medical tests to identify specific mutations in a person’s genes. These tests, which are continually evolving, have diverse applications, including assessing cancer risk. Predictive genetic testing, in particular, looks for inherited gene mutations

EDX Medical Group plc

EDX Medical Group participating in “The Pub Test” Investor Evening

EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced its participation in “The Pub Test” Investor Evening. This event is co-hosted